KBP-042
KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance.
For research use only. We do not sell to patients.
- Formula: C149H244N44O48S2
- Molecular Weight:3483.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 6 weeks old at study start, fed 60% fat kcal high-fat diet for 10 weeks to induce obesity and prediabetic status)[1]
-
Dosage:0.625-10 μg/kg (8-week treatment); 5 μg/kg (hyperinsulinemic-euglycemic clamp)
-
Administration:s.c.; daily; 56 days (8-week treatment); 21 days (hyperinsulinemic-euglycemic clamp)
-
Result:Induced a dose-dependent, sustained weight loss up to 20% compared to high-fat diet vehicle; caused significant weight reduction at 2.5, 5, and 10 μg/kg vs. vehicle. Reduced epididymal and perirenal adipose tissue weights significantly at 10 μg/kg; reduced perirenal adipose tissue also at 2.5 and 5 μg/kg. Reduced hepatic triacylglycerol accumulation significantly at 2.5 μg/kg and 10 μg/kg. Increased plasma adiponectin significantly at 1.25, 2.5, 5, and 10 μg/kg; reduced plasma leptin significantly at 10 μg/kg. Showed impaired glucose tolerance (increased total area under the curve) at 10 μg/kg in acute OGTT, but reduced glucose total area under the curve at 2.5, 5, and 10 μg/kg vs. vehicle after 3 weeks of chronic treatment; improved glucose tolerance at 5 and 10 μg/kg after 7 weeks. Reduced insulin total area under the curve at 1.25-10 μg/kg after 3 weeks of IVGTT and at 2.5 and 5 μg/kg after 7 weeks while maintaining glucose tolerance. Increased glucose infusion rate by 82% vs. high-fat diet vehicle (and 27% vs. normal diet controls) during hyperinsulinemic-euglycemic clamp at 5 μg/kg.
Chemical Information
-
Molecular Weight 3483.93
-
Formula C149H244N44O48S2
-
Sequence
Ac-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ala-Asn-Ala-Pro-NH2 (Disulfide bridge: Cys1-Cys7)
-
Sequence Shortening
Ac-CSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 (Disulfide bridge: Cys1-Cys7)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Large-size fat particle sorting
Large-size fat particle sorting is widely used to isolate cells up to 200 μm in diameter. Single-cell flow sorting will allow greater insight into adipocyte heterogeneity by identifying gene expression, protein composition, and metabolic signatures at the single-cell level.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)